Several clinical trials have evaluated 17-AAG in combination with kinase inhibitor drugs, including Raf inhibitor sorefenib and human epidermal growth factor receptor 2 (HER2) inhibitor trastuzumab, in VHL mutant kidney cancer and HER2-positive breast cancers, respectively [64,65]. Here, ERBB2 is linked to kidney cancer.